Loading
ComboMATCH is the sequel to NCI-MATCH. Its lesson was that one targeted drug for one mutation rarely works, so this trial tests pairs of drugs chosen because laboratory models showed the pair beats either alone.
ComboMATCH opened in April 2023 under ECOG-ACRIN with the same national machinery as NCI-MATCH but a different entry route: instead of a single central assay, patients can be registered on the strength of a genomic report from any NCI-designated laboratory, which removes the biopsy and turnaround delay that kept many NCI-MATCH patients from ever being assigned.
Each sub-study pairs a targeted drug with a second agent, chosen where patient-derived xenograft or other preclinical work showed the combination overcomes the resistance that defeated single agents, and several sub-studies are randomised against the single drug so that the contribution of the partner is measured rather than assumed. The registration protocol plans for close to 3,000 patients across the sub-studies.
Nothing has reported yet. What the trial is meant to change is the evidentiary standard for precision oncology: if matched combinations succeed where NCI-MATCH's single agents failed, the genotype-first approach survives in a new form; if they do not, the lesson will be that tissue and lineage matter more than the alteration list.
Shares Master protocol (platform, basket and umbrella trials), Rare cancers, Basket, umbrella, and platform trials, Comprehensive genomic profiling.
Shares Master protocol (platform, basket and umbrella trials), Rare cancers, Basket, umbrella, and platform trials, Trial design, endpoints and cost.
Shares Master protocol (platform, basket and umbrella trials), ECOG-ACRIN Cancer Research Group, Basket, umbrella, and platform trials, National Cancer Institute (NIH).
Shares Master protocol (platform, basket and umbrella trials), Rare cancers, Basket, umbrella, and platform trials, National Cancer Institute (NIH).
Shares NCI-MATCH (EAY131), ECOG-ACRIN Cancer Research Group.
Shares Basket, umbrella, and platform trials, Trial design, endpoints and cost, Comprehensive genomic profiling.
Shares ECOG-ACRIN Cancer Research Group, Basket, umbrella, and platform trials, Trial design, endpoints and cost, National Cancer Institute (NIH).
Shares NCI-MATCH (EAY131), Master protocol (platform, basket and umbrella trials), Basket, umbrella, and platform trials, Trial design, endpoints and cost.